The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...

Another TNF inhibitor, certolizumab (Cimzia; UCB), which is approved for Crohn's disease and rheumatoid arthritis, showed good efficacy in Phase II psoriasis trials 2. However, no development of ...

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money.

(NASDAQ:DERM) and UCB (Euronext:UCB) today announced the companies have agreed to end their development and commercialization agreement for CIMZIA (certolizumab pegol) in psoriasis. Following ...

New medicines for treating migraines, psoriasis and liver cancer have been approved for use by NHS Scotland. The three drugs have been licensed by the Scottish Medicines Consortium for use in the ...